Postoperative recurrence (POR) is a major challenge in the long-term management of Crohn’s disease (CD), affecting up to 70% ...
Therapeutic progress for fibrostenotic Crohn’s disease has been stalled in a paradox: Antifibrotic drugs require endpoints ...
Vedolizumab is associated with lower venous thromboembolism and cardiovascular event risk than TNF inhibitors in UC.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results